Here’s a startling fact: despite the proven benefits of vaccines, millions of people remain unprotected, leaving healthcare systems under constant strain. But why is this still happening, and what can we do about it? A groundbreaking new analysis reveals that vaccines significantly reduce hospitalizations for both flu and COVID-19, yet their full potential remains untapped. And this is the part most people miss: even small increases in vaccination rates could dramatically ease the burden on hospitals.
The study, conducted by RespiCompass in collaboration with international modeling teams, highlights a striking disparity in vaccine uptake across countries. While vaccines have been shown to prevent severe illness, influenza vaccination rates in most EU/EEA nations fall short of World Health Organization (WHO) targets for at-risk groups. Worse still, COVID-19 vaccination rates are declining—a trend that raises serious concerns. Is this a failure of public health communication, or are there deeper issues at play?
By combining models to simulate various scenarios, researchers projected that between August 5, 2024, and June 1, 2025, vaccination programs in EU/EEA countries could prevent 26–41% of flu-related hospitalizations among adults aged 65 and over. For COVID-19, the reduction in hospitalizations for the same age group could range from 14–20%. These estimates were based on vaccine effectiveness rates of 60% for flu vaccines and 75% for COVID-19 vaccines, supported by the latest evidence. However, the actual impact varied due to differences in vaccine uptake, transmissibility, and immunity waning.
But here’s where it gets controversial: while these findings underscore the value of vaccines, they also reveal a missed opportunity. Both seasonal flu and COVID-19 vaccination programs have the potential to drastically reduce hospital pressure, yet their success hinges on public participation. For instance, even modest increases in vaccination rates could lead to significant drops in hospitalizations, saving lives and resources. Yet, why are so many still hesitant or unaware of these benefits?
This analysis isn’t just about numbers—it’s a call to action. Collaborative modeling studies like this one can inform cost-effectiveness analyses, resource planning, and stronger public health messaging at both EU/EEA and national levels. For healthcare workers, policymakers, and science communicators, these insights are invaluable for refining vaccination strategies.
So, what do you think? Are we doing enough to promote vaccination, or is there more we could—and should—be doing? Share your thoughts in the comments, and let’s spark a conversation that could shape the future of public health.
